International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 277-281 , 1 June 2002

Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapy

  • Noel M Kramer (D.O.)

      Affiliations

    • Corresponding Author InformationReprint requests to: Noel M. Kramer, D.O., Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111 USA. Tel: (215) 728-2940; Fax: (215) 728-2868
    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Alexandra L Hanlon, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Eric M Horwitz, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Wayne H Pinover (D.O.)

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Gerald H Hanks, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

Received 16 July 2001 ,Revised 28 December 2001 ,Accepted 7 January 2002.

References 

  1. Epstein JI, Walsh PC, Carmichael M, et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–374
  2. American Joint Committee on Cancer . Prostate. In:  Beahrs OH,  Henson DE,  Hutter RVP,  Kennedy BJ editor. Manual for the staging of cancer. 4th ed.. Philadelphia, PA: JB Lippincott; 1992;p. 181–186
  3. Pinover WH, Hanlon AL, Lee WR, et al.  Prostate carcinoma patients upstaged by imaging and treated with irradiation. Cancer. 1996;77:1334–1341
  4. Benson MC, Whang IS, Pantuck A, et al.  Prostate specific antigen density (A means of distinguishing benign prostatic hypertrophy and prostate cancer). J Urol. 1991;147:815–816
  5. Benson MC, Whang IS, Olsson CA, et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1991;147:817–821
  6. Veterans Administration Cooperative Urological Research Group Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol. 1974;111:58–64
  7. Hanks GE, Lee WR, Hanlon AL, et al.  Conformal technique for dose escalation for prostate cancer (Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥ 10 ng/mL). Int J Radiat Oncol Biol Phys. 1996;35:861–868
  8. Movsas B, Hanlon AL, Teshima T, et al.  Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer. 1997;80:1093–1102
  9. International Commission on Radiation Units and Measurements . Prescribing, recording and reporting photon beam therapy. ICRU Report. 1993;50:29–33
  10. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  12. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression following radical retropubic prostatectomy. Cancer. 1993;71:3582–3593
  13. Epstein JI, Carmichael M, Partin AW, et al.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with five years follow-up. J Urol. 1993;149:1478–1481
  14. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In:  Walsh PC,  Retick AB,  Stamey TA,  Vaughn ED editor. Campbell’s urology. Philadelphia, PA: WB Saunders Co; 1992;p. 1200–1201
  15. Horwitz EM, Hanlon AL, Pinover WH, et al.  The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1998;41:519–523
  16. Zelefsky M, Leibel S, Gaudin P, et al.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  17. Pound CR, Partin AW, Epstein JI, et al.  PSA following anatomical radical retropubic prostatectomy (An interim report). Urol Clin North Am. 1997;24:395–406
  18. Pound CR, Walsh PC, Epstein JI, et al.  Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World J Urol. 1997;15:373–377
  19. Lerner SE, Seay TM, Blute ML, et al.  Prostate specific antigen detected prostate cancer (clinical stage T1c) (An interim analysis). J Urol. 1996;155:821–826
  20. Hanks GE, Hanlon AL, Pinover WH, et al.  Radiation therapy as treatment for stage T1c prostate cancers. World J Urol. 1997;15:369–372

PII: S0360-3016(02)02706-2

International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 277-281 , 1 June 2002

Article Tools

* Image Usage & Resolution